Search bioRxiv⌕ Search

Biology subjects

Jones, H. A.

Publications and source records attributed to Jones, H. A..

3 recordsLinked to original sources

Biomolecular design through latent reasoning with RFD4-Proteina

Biomolecular design requires finding chemically and geometrically compatible arrangements of interacting atoms and molecules. The complexity of problems which can be tackled by deep learning design models is limited by both the molecular landscape they encompass and their ability to explore that landscape effectively. Here we introduce RFD4-Proteina, which addresses these limitations through intrinsic and extrinsic reasoning within a shared chemical and conformational latent space. The latent space encompasses standard and modified amino acids, sugars, DNA, and RNA, with force-field supervision favoring physically plausible atomic reconstructions. Within this space, intrinsic reasoning uses recurrent refinement to adaptively allocate computation, while extrinsic reasoning guides search with arbitrary constraints such as energetic or geometric criteria. Across in silico protein design benchmarks, RFD4-Proteina achieves higher design success rates at greater generation throughput than all previous methods evaluated, with further gains from conformational flexibility, recurrent refinement, and search. The same model performs equivalently to or better than state-of-the-art specialist methods for side-chain packing, sequence design, conformational sampling, and design refinement. We demonstrate the power and versatility of RFD4-Proteina experimentally by designing specific and cross-reactive binders to therapeutically relevant targets, recognizing phosphorylations, controlling glycosylation, and creating enzymes that catalyze both bond-breaking and bond-forming reactions, including a first proof-of-concept demonstration of a de novo designed enzyme for active pharmaceutical ingredient synthesis. By unifying diverse chemistry, conformational flexibility, and scalable reasoning in a single physically grounded latent space, RFD4-Proteina expands the frontier of biomolecular design.

bioengineering↗

New inhibitors of the Pseudomonas aeruginosa enzyme, PqsE, and methods assessing their potential to induce a conformational change via active site binding

Pseudomonas aeruginosa is an opportunistic pathogen known for its ability to produce virulence factors and form biofilms. These, among many other traits, enable P. aeruginosa to cause infections, evade host immune responses, and resist treatment with antimicrobial agents. Both the ability to form biofilms and produce virulence factors are regulated via the bacterial cell-cell communication process called quorum sensing. A key molecular event that enables quorum sensing in P. aeruginosa is the physical interaction between an enzyme, PqsE and a master quorum-sensing receptor/transcription factor RhlR, which regulates the expression of a wide variety of virulence-associated genes. Previous work identified active site mutations in PqsE that induce a conformational change weakening the interaction with RhlR. These active site mutations weakened the PqsE-RhlR interaction to the extent that several virulence genes were not activated, and the mutant strains of P. aeruginosa failed to colonize the lungs of a mouse. In this study, we designed a series of molecules to probe binding in the active site of PqsE as a strategy for inhibiting the PqsE-RhlR interaction and thus, the activation of RhlR-controlled genes in P. aeruginosa. HJ1 and HJ5 are new molecules that both bind in the active site of PqsE, and while HJ5 appears to bind in an alternate mode compared to HJ1, it does not induce a conformational change to weaken the PqsE-RhlR interaction. Here, we introduce multiple experimental approaches to assess the way in which these new molecules engage in the PqsE active site. HJ5 can serve as a promising starting point for the development of molecules that target the PqsE active site and allosterically inhibit the interaction with RhlR, thus decreasing virulence in P. aeruginosa.

biochemistry↗

Screening of FDA-approved small molecules to discover inhibitors of the Pseudomonas aeruginosa quorum-sensing enzyme, PqsE

Pseudomonas aeruginosa is a notorious pathogen that is a leading cause of hospital-acquired infections. Due to its heightened resistance to a broad range of antibiotics, there is great need for new antimicrobial agents that are effective in treating P. aeruginosa infections. One attractive option for exploring new antibiotic targets is the quorum sensing (QS) pathway, as it governs many of the pathogenic behaviors that allow P. aeruginosa to stage and maintain infections. Within the QS pathway, there is a key protein-protein interaction between an enzyme, PqsE, and one of the master QS regulators, RhlR. Although its catalytic function is dispensable for its interaction with RhlR, previous mutagenic work characterizing the active site of PqsE identified active site mutations that induce a conformational change in PqsE, preventing it from forming a complex with RhlR. These active site mutations, when introduced stably into the genome of P. aeruginosa, also lead to a significant decrease in production of a key toxin, pyocyanin, and prevent colonization in the lungs of a murine host. These findings encourage drug discovery efforts to identify small molecules that bind in the active site of PqsE and induce a conformational change similar to the ones induced by particular amino acid substitutions in the active site. Here, we performed a fluorescence polarization screen to identify molecules that bind in the active site of PqsE. We screened a library of FDA-approved drugs, with the intention of potentially repurposing a known molecule for the treatment of P. aeruginosa infections. Three molecules were identified, two of which showed inhibitory activity that was consistent with a competitive mode of inhibition. One hit molecule, Apomorphine, had a distinctly different inhibitory profile, and is potentially binding outside of the active site to allosterically inhibit enzyme activity of PqsE. All three hit molecules were tested in an in vivo enzyme activity assay, and one of the competitive inhibitors, Vorinostat, was found to inhibit intracellular PqsE. Vorinostat is now being explored as a candidate for synthetic derivatization to inhibit the PqsE-RhlR protein-protein interaction via binding in the PqsE active site.

biochemistry↗